Cancer Letters
Volume 210, Issue 1 , Pages 7-15 , 8 July 2004

Limited tumor growth (HT29) in vivo under RO205-2349 is due to increased apoptosis and reduced cell volume but not to decreased proliferation rate

This publication is dedicated to Prof. H. Marquardt on the occasion of his retirement

  • Marcus Katoh

      Affiliations

    • Institute for Anatomy II: Experimental Morphology, University Hospital Hamburg-Eppendorf, Martinistrasse 52, Hamburg D-20246, Germany
    • ,
  • Susanne Feldhaus

      Affiliations

    • Institute for Anatomy II: Experimental Morphology, University Hospital Hamburg-Eppendorf, Martinistrasse 52, Hamburg D-20246, Germany
    • ,
  • Tobias Schnitzer

      Affiliations

    • Roche Diagnostics GmbH, Werk Penzberg, Nonnenwald 2, D-82372 Penzberg, Germany
    • ,
  • Sabine Bauer

      Affiliations

    • Roche Diagnostics GmbH, Werk Penzberg, Nonnenwald 2, D-82372 Penzberg, Germany
    • ,
  • Udo Schumacher

      Affiliations

    • Institute for Anatomy II: Experimental Morphology, University Hospital Hamburg-Eppendorf, Martinistrasse 52, Hamburg D-20246, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-40-42803-3586; fax: +49-40-42803-5427

Received 24 January 2003 ,Revised 9 January 2004 ,Accepted 12 January 2004.

References 

  1. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358:771–774
  2. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, et al.  Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res. 1994;22:5628–5634
  3. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell Biol. 1995;15:351–357
  4. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. Mol. Cell Biol. 1996;16:3410–3419
  5. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147–1156
  6. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann. NY Acad. Sci. 1996;804:266–275
  7. Latruffe N, Vamecq J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie. 1997;79:81–94
  8. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, et al.  The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 1997;272:18779–18789
  9. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al.  Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46:1319–1327
  10. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem. Biophys. Res. Commun. 1996;222:844–851
  11. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803–812
  12. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83:813–819
  13. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995;270:12953–12956
  14. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res. 1999;90:75–80
  15. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al.  Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl Acad. Sci. USA. 1997;94:237–241
  16. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl Acad. Sci. USA. 1999;96:3951–3956
  17. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al.  Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell. 1998;1:465–470
  18. Altiok S, Xu M, Spiegelman BM. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 1997;11:1987–1998
  19. Mitchell BS, Horny HP, Schumacher U. Immunophenotyping of human HT29 colon cancer cell primary tumours and their metastases in severe combined immunodeficient mice. Histochem. J. 1997;29:393–399
  20. Mitchell BS, Schumacher U. Use of immunodeficient mice in metastasis research. Br. J. Biomed. Sci. 1997;54:278–286
  21. Johnston PG, O'Brien MJ, Dervan PA, Carney DN. Immunohistochemical analysis of cell kinetic parameters in colonic adenocarcinomas, adenomas, and normal mucosa. Hum. Pathol. 1989;20:696–700
  22. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 1998;4:1046–1052
  23. Schumacher U, Adam E, Feldhaus S, Katoh M, Lane DP. Cell differentiation and chemotherapy influence p53 and Mdm2 immunoreactivity in human HT29 colon cancer cells grown in scid mice. Cancer Lett. 2001;166:215–221
  24. Hall PA. Assessing apoptosis: a critical survey. Endocr. Relat. Cancer. 1999;6:3–8
  25. Sharma R, Adam E, Schumacher U. The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. Br. J. Cancer. 1997;76:1011–1016
  26. van Dam PA, Lowe DG, Watson JV, Jobling TW, Chard T, Shepherd JH. Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2. Cancer. 1991;68:169–177
  27. Jojovic M, Schumacher U. Quantitative assessment of spontaneous lung metastases of human HT29 colon cancer cells transplanted into SCID mice. Cancer Lett. 2000;152:151–156
  28. Gabbert H, Wagner R, Moll R, Gerharz CD. Tumor dedifferentiation: an important step in tumor invasion. Clin. Exp. Metastasis. 1985;3:257–279
  29. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem. Biophys. Res. Commun. 2000;270:400–405
  30. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl Acad. Sci. USA. 1998;95:8806–8811
  31. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344–3352
  32. Dazard JE, Piette J, Basset-Seguin N, Blanchard JM, Gandarillas A. Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size. Oncogene. 2000;19:3693–3705
  33. Wehling M, Kuhls S, Armanini D. Volume regulation of human lymphocytes by aldosterone in isotonic media. Am. J. Physiol. 1989;257:E170–E174

PII: S0304-3835(04)00055-2

doi: 10.1016/j.canlet.2004.01.010

Cancer Letters
Volume 210, Issue 1 , Pages 7-15 , 8 July 2004

Article Tools

* Image Usage & Resolution